Background: TMPRSS4 is a membrane-anchored protease involved in cell migration and invasion in different cancer types including lung cancer. TMPRSS4 expression is increased in NSCLC and its inhibition through shRNA reduces lung metastasis. However, molecular mechanisms leading to the protumorigenic regulation of TMPRSS4 in lung cancer are unknown.
Lung cancer is a critical problem in public health. It represents the most frequent tumour type in men and the second in women, and the 5-year survival rate remains inferior to 20% (Jemal et al, 2010) . More than 60% of NSCLC patients present locally advanced, unresectable or metastatic (stage III/IV) tumours at the time of diagnosis, which fatally concludes in death within few months after diagnosis. In spite of the advent of targeted therapies, which has been a breakthrough for NSCLC management, only a small percentage of patients will benefit from them. Therefore, there is a need for identifying new potential therapeutic targets against which more effective treatments may be developed.
Altered expression of proteases is currently considered as a hallmark of cancer, as malignant cells need proteolytic activities to promote growth, motility and invasion (Roy et al, 2009) . Type II transmembrane serine proteases (TTSPs) are characterised by the presence of an N-terminal transmembrane domain that anchors these proteases to the plasma membrane. TTSPs include 18 members that can be divided into four groups. Examples of TTSPs related to cancer are hepsin, matriptase, HAT/DESC and TMPRSS4 (Szabo and Bugge, 2008) .
TMPRSS4 comprises a short N-terminal cytoplasmic domain, a transmembrane domain and a large extracellular domain that contains the catalytic activity. TMPRSS4 is synthesised as an inactive zymogen that needs to be activated (Netzel-Arnett et al, 2003) . However, both the substrates and activators of this serine protease are largely unknown. TMPRSS4 participates in the regulation of cellular signalling events at the plasma membrane and in the extracellular matrix (Hooper et al, 2001) . TMPRSS4 is upregulated in pancreatic, colon, lung, ovary and thyroid cancers, where it has been suggested as a diagnostic marker (Kebebew et al, 2005) . In a previous work, we demonstrated that TMPRSS4 is highly expressed in lung tumours compared with normal lung, particularly in squamous cell carcinomas (SCC) as compared with adenocarcinomas (AC). We also demonstrated that high TMPRSS4 mRNA levels in SCC are associated with poor prognosis (Larzabal et al, 2011) . Moreover, a knockdown strategy to reduce TMPRSS4 levels in lung tumour cells resulted in a significant impairment of metastasis in animal models (Larzabal et al, 2011) .
Studies of biological activity in colon cancer have reported that elevated TMPRSS4 expression induces epithelial-to-mesenchymal transition (EMT) of cancer cells and promotes metastasis (Jung et al, 2008; Kim et al, 2010) . Further analysis of TMPRSS4-mediated signalling in colon cancer cells suggested that multiple downstream signalling pathways are activated. These included Src, ERK1/2, AKT, FAK and Rac1, resulting in E-cadherin downregulation and induced expression of integrin a5b1, a critical adhesion molecule involved in the acquisition of an EMT phenotype and cell motility (Maschler et al, 2005) . Inhibition of PI3K or Src with specific compounds decreases cell invasiveness and actin rearrangement mediated by TMPRSS4. Moreover, functional blockade of integrin a5b1 demonstrated that this integrin has an important role in TMPRSS4-mediated effects (Kim et al, 2010) . In spite of these data, the molecular regulation of TMPRSS4 in cancer cells is poorly understood.
The aim of this study was to identify molecular mechanisms involved in the protumorigenic regulation of TMPRSS4 in NSCLC. Through a microarray analysis, we discovered that the miR-205 gene (MIR205HG) was consistently overexpressed upon TMPRSS4 downregulation. We demonstrate here that overexpression of miR-205 promotes an epithelial phenotype and inhibits tumour cell migration and metastasis formation in lung cancer models. Moreover, we have identified integrin a5b1 (a proinvasive protein) as a new miR-205 direct target in NSCLC; we also show a novel molecular mechanism that connects TMPRSS4 with integrin a5b1 through miR-205.
MATERIALS AND METHODS
Cell culture. All human lung cancer cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA) and were maintained in RPMI (Sigma, Madrid, Spain) with 10% fetal bovine serum (Thermo Scientific, Waltham, MA, USA) and 1% penicillin-streptomycin (Lonza, Basel, Switzerland), at 37 1C and 5% CO 2 atmosphere.
H358 and H441 cell clones with a reduction of TMPRSS4 (shTMP4) and their corresponding controls (carrying the empty vector; shCtrl) were previously described by our group (Larzabal et al, 2011) .
Immortalised normal human bronchial epithelial cells (HBECs) have been previously characterised (Ramirez et al, 2004) . These cell lines were kindly provided by Dr J.D. Minna (University of Texas Southwestern Medical Center, Dallas, TX, USA). Cells were maintained in keratinocyte serum-free medium supplemented with human recombinant epidermal growth factor (EGF) and bovine pituitary extract (Life Technologies, Carlsbad, CA, USA).
miRNA transfection. H2170, H441 and A549 cell lines were transfected with miRNASelect pEP-miR Null control vector or miRNASelect pEP-hsa-miR-205 vector (Cell Biolabs, San Diego, CA, USA) using GeneJuice reagent (Merck Millipore, Darmstadt, Germany) . Transfected cell clones were selected with puromycin (2 mg ml À 1 ).
Integrin a5 inhibition. We used integrin a5 shRNA lentiviral particles (Santa Cruz Biotechnology, Dallas, TX, USA) to inhibit integrin a5 expression in the H2170 cell line. Infection with shRNA was performed with polybrene according to the manufacturer's protocol. Stable clones were selected with 1 mg ml À 1 puromycin. The integrin a5 expression was analysed by western blot and qPCR.
RNA extraction and quantitative real-time PCR. RNA isolation and qPCR was carried out as previously described (Larzabal et al, 2011) . Assays were performed to quantify mRNA levels of human E-cadherin, fibronectin, ZEB1/ZEB2 and integrin a5. The primer sequences are shown in Supplementary Table 1 .
To detect mature miR-205 expression, TRIzol reagent (Invitrogen, Carlsbad, CA, USA) was used to isolate total RNA. For the quantification of this miRNA, stem-loop RT of 20 ng total RNA was run using the TaqMan MicroRNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA) with specific primers for miR-205 and RNU48 as endogenous control (Applied Biosystems). Subsequently, the qPCR amplifications were performed with TaqMan 2 Â Universal PCR Master Mix, No AmpErase UNG (Applied Biosystems) and specific primers for miR-205 and RNU48 (Applied Biosystems). Relative miR-205 levels were normalised to RNU48 expression. Data are given as 2 À DDCt or 2 À DCt .
Proliferation and clonogenic assays. To determine proliferation of H2170 and H441 cells and their miR-205 expressing clones, 1200 cells per well were seeded in 96-well plates. Ninety-six hours after plating, MTT assays were performed following the manufacturer's protocol (Sigma).
To evaluate the clonogenic potential of miR-205 expressing clones, 500 cells per well were plated into six-well plates in adherent conditions. After 10 days in culture, colonies were fixed with 4% buffered formalin (Panreac, New Jersey, NY, USA) and stained with 2% crystal violet. The number of colonies per well was determined.
Anchorage-independent growth assay. Soft-agar assay was used to determine the ability of miR-205-expressing clones to grow under anchorage-independent conditions. Each well of a six-well plate was coated with culture medium containing 0.6% agarose. Upon solidification, a layer of 0.3% agar in culture medium carrying 2000 cells per well was placed on top of the agarose. Colonies were stained with MTT and counted after 2 weeks of incubation.
Cell cycle analysis. For cell cycle distribution analysis, adherent and floating cells were fixed in 70% ethanol for 1 h (or until analysis) at 4 1C. Cells were then rehydrated in PBS, treated with RNase A (0.2 mg ml À 1 , Sigma) for 1 h at 37 1C and stained with 7AAD (0.02 mg ml À 1 , Sigma). Cells were analysed in a flow cytometer (FACSCalibur, BD) . Percentages of cells in the Sub-G 0 , G 0 /G 1 , S and G 2 /M phases were determined.
Migration assays. Migration assays were conducted in a Boyden chamber for the H2170 and A549 cell lines. A total of 15 000 cells per well in serum-free medium were seeded in the upper transwell of 24-well plates (Costar, Tewksbury, MA, USA). Medium with 10% of serum was used as a chemoattractant and was placed in the lower compartment. After 48 h, cells in the top chamber were wiped with a cotton swab, and cells in the lower compartment were fixed with 4% formalin and stained with crystal violet. The number of migratory cells was evaluated with a Leica DMIL LED microscope using the LAS EZ software (Leica Microsystems, Wetzlar, Germany).
H441 cells did not migrate through the transwell in Boyden chambers (unpublished observations). For this reason, we examined migration of this cell line with an in vitro model of wound healing. Cells were grown until confluence, and a 20-p micropipette tip was used to create a linear scratch in the monolayer. Pictures of the wounds were taken right after the scratching and 24 h later with a Nikon Eclipse photomicroscope (Nikon, Kingston, UK) using the ACT-2U1.6 software (Nikon). The empty surface between the wound edges was measured with the TScratch analysis software (Zurich, Switzerland).
Adhesion assay. Single-cell suspensions were rinsed with serumfree medium supplemented with 0.5% BSA, and 30 000 cells per well were seeded in 96-well plates precoated with 3% BSA (control), fibronectin (20 mg ml À 1 per well) or collagen type I (50 mg ml À 1 per well). After 30 min incubation to let cells adhere to the substrates at 37 1C, wells were washed with PBS to remove the floating cells. Attached cells were fixed in 4% paraformaldehyde and stained with 0.5% toluidine blue. To obtain the adherent cell number, stained cells were treated with 1% SDS, and the absorbance at 595 nm was measured using a Sunrise spectrophotometer (Tecan, San Jose, CA, USA).
E-cadherin and fibronectin immunofluorescence. Control cells and miR-205-expressing cell clones were grown in slide chambers until confluence. Cells were fixed by immersion in acetone:methanol (1 : 1) solution for 10 min at À 20 1C. Then, non-specific binding sites were blocked with 2% BSA, and slides were incubated with primary anti-E-cadherin (BD Bioscience, San Jose, CA, USA) or anti-fibronectin (Abcam, Cambridge, UK) antibodies at 1 : 100 dilution for 2 h at room temperature. Slides were then incubated in darkness with the secondary antibody (488 Alexa Fluor dye, Invitrogen) for 1 h at room temperature. For nuclei staining, samples were incubated with 0.1 mg ml À 1 DAPI. A hydrophilic mounting medium (SlowFade antifade) was used, and coverslips were sealed with nail polish. For visualisation and acquisition of images, an Axio Imager Z1 (ZEISS) epifluorescence microscope equipped with a CoolSnap CCD camera was used.
Microarray hybridisation and bioinformatic analysis. Transcriptional profiling was done with the Affymetrix Human Gene 1.0 ST microarray according to the manufacturer's protocol. Both background correction and normalisation were done with RMA (Robust Multichip Average) algorithm (Irizarry et al, 2003) . Then, a filtering process was performed to eliminate low expression probe set intensities for each probe, recorded in CEL files and data were analysed. The analysis of significant gene expression changes in shTMP4 samples compared with expression in control cells was performed by Z-score transformation of fold-change distributions (Cheadle et al, 2003) . A threshold of |z|42.3 (P-valueo0.01) was set to select genes for further analysis. The selection of genes differentially expressed in miR-205-overexpressing cells with respect to control cells was performed using the criteria based on the fold-change value. Probe sets were selected as significant using a cutoff value of 2. The set of differentially expressed genes was compared with the miRNA-predicted targets stored in public databases (Betel et al, 2008; Griffiths-Jones et al, 2008; Friedman et al, 2009) . As a result, putative microRNA target genes with altered expression were identified.
Western blotting. Protein extraction and western blot were carried out as previously described (Ponz-Sarvise et al, 2011) . The primary antibodies (diluted at 1 : 1000) were as follows: antihuman ITGa5 (Sigma), anti phospho-Src (Cell Signaling, Danvers, MA, USA) and anti-Src (Cell Signaling). An anti-human b-actin antibody (Sigma) at 1 : 10 000 dilution was used as a loading control. Horseradish peroxidase-labelled secondary antibodies (GE Healthcare, Waukesha, WI, USA) against the corresponding primary antibodies were used. Immunoreactive bands were visualised by a chemiluminescent method using the LumilightPLUS kit (Roche, Palo Alto, CA, USA).
Generation of H2170 TGL-expressing cells for in vivo imaging.
Amphopack-293 packaging cells (Clontech, Madison, WI, USA) cultured with DMEM and 10% fetal bovine serum were transfected with the pSFG NES TGL purified plasmid as previously described (Larzabal et al, 2011) . After 48 h in culture, virus containing supernatant was added to parental H2170 cells and H2170-miR-205-expressing cell clones. To increase the efficiency of infection, 7.5 mg ml À 1 polybrene (Sigma) was added to the virus containing supernatants. Vector containing GFP þ cells were sorted by FACS (FACSAria Ilu). More than 90% of the cells were confirmed to express the reporter construct (Supplementary Figure 1A) .
In vivo experiments. Animal studies were carried out according to the ethical guidelines established by our Institution (University of Navarra), under an approved animal protocol (069/11). For the lung metastasis model, 1.5 Â 10 6 H2170 cells containing the control vector (miR-Scr) or the miR-205 overexpressing clones (miR-205#2 or miR-205#3) infected with the TGL reporter vector were injected in the tail vein in NOD SCID ILRb2 null (NSG) mice. Four mice per group were used. Lung tumour development was monitored by detection of luciferase photon emission, using a Xenogen (Xenogen Inc., Alameda, CA, USA) (IVIS 100 series) living image system. Anaesthetised mice were injected intraperitoneally with 3 mg of D-Luciferin (Promega, Fitchburg, WI, USA) diluted in PBS, 5 min before light caption. The image acquisition time was in the range of 5 min. Data analyses were performed with the Living Image Igor Pro (Xenogen) software coupled to the IVIS system. Photon counts were calculated for each mouse using a circular region of interest.
To study the effect of miR-205 on primary tumour growth, 10 Â 10 6 H2170 cells and their corresponding miR-205-overexpressing clones (miR-205#2 or miR-205#3) were injected subcutaneously into the flanks of the mice in a 1 : 1 PBS/Matrigel solution (BD). A similar experiment was conducted to assess whether knockdown of ITGa5 (shITGa5 H2170 cells) would decrease primary tumour growth with respect to controls. Tumour volumes were calculated with the formula: V ¼ length Â (width) 2 /2.
Immunohistochemistry. Tumours were excised, fixed, paraffinembedded and cut in 5 mm thick sections, which were placed on slides. Slides were deparaffinised, rehydrated and treated for 12 min with 3% H 2 O 2 (Panreac) in water to quench the endogenous peroxidase activity. For caspase-3, antigen retrieval was performed by heating the sections in a microwave oven in 1 mM EDTA (pH 8). Tissues were then blocked with normal goat serum in TBS (30 min, RT). Incubation with the following primary antibodies was done overnight at 4 1C: anti-cleaved caspase-3 Asp175 (Cell Signaling) at 1 : 200 dilution, anti-PCNA (Clone PC10; Dako, Glostrup, Denmark) at 1 : 400 dilution and antiintegrin a5 (Sigma) at 1 : 50 dilution. After incubation with Envision anti-rabbit or anti-mouse system (Dako), peroxidase activity was developed with DAB (3,3 0 -diaminobenzidine; Dako). Finally, slides were counterstained with haematoxylin, dehydrated and mounted with DPX (VWR).
Renilla luciferase assay. The renilla luciferase constructs with the 3 0 -untranslated region (UTR) of ITGa5 were made with the following oligonucleotides:
These oligonucleotides contain the target site sequence or the mutated version (indicated in bold letters), which is complementary to the seed sequence of miR-205. Hybridised oligonucleotides were ligated into the XbaI-NotI site of the renilla reporter vector (pRL-SV40; Promega). GeneJuice reagent was used to co-transfect the renilla-ITGa5-3 0 UTR vector or the Renilla-ITGa5-3 0 UTRmut, and a control vector containing firefly luciferase (pGL3-basic; Promega), together with either pre-miR-205 or scramble precursor-miR vectors. Renilla luciferase activity was measured 48 h after transfection with the Dual-Luciferase System (Promega) in a Berthold Luminometer (Lumat LB 9507).
Statistical analysis. Statistical differences between groups were examined with the Student's t-test or ANOVA for unpaired parametric variables and the Mann-Whitney U-test or KruskalWallis for unpaired non-parametric variables. Normality was analysed with the Shapiro-Wilks test. Data were processed with the SPSS statistical software (SPSS-IBM Inc., Chicago, IL, USA) (version 17.0 for Windows SPSS) and GraphPad Prism 5 software (GraphPad Software Inc., San Diego, CA, USA). P-values lower than 0.05 were considered as statistically significant.
RESULTS
TMPRSS4 knockdown upregulates miR-205 expression. Previous studies have shown that TMPRSS4 has a role in cell migration and invasion (Kim et al, 2010) . We have demonstrated that TMPRSS4 expression is increased in NSCLC and that its inhibition through shRNA reduces lung metastasis (Larzabal et al, 2011) . Because molecular mechanisms activated by TMPRSS4 are unknown, we used an shRNA strategy to knockdown this protease in H358 and H441 cells, in search of genes with an altered expression. Clones H358 shTMP4-2 and shTMP4-3 and H441 shTMP4 (with a reduced TMPRSS4 expression) were selected for the microarray analysis. We have previously shown that these clones have reduced proliferative and migratory ability compared with their respective controls (H358 shCtrl and H441 shCtrl) (Larzabal et al, 2011) .
A list of 287 probes was found to be deregulated by 4two-fold in the three cell clones analysed. From those, 176 probes corresponded to non-annotated sequences. We then focused our analysis in those genes whose expression trend was the same (either upregulation or downregulation) in the three clones ( Figure 1A) . Twenty-nine genes followed this pattern (12 of them overexpressed and 17 of them underexpressed). As expected, TMPRSS4 was one of the downregulated genes of this set. Other downregulated genes that have a role in cancer cell adhesion included DDR1 and CLEC18A. DDR1 has been shown to promote lung cancer metastasis to the bone, and its expression correlates with poor prognosis in NSCLC patients (Valencia et al, 2012) .
One of the upregulated genes found in the list was MIR205HG. This microRNA has been described as a tumour suppressor gene in different tumour types (Song and Bu, 2009; Majid et al, 2011) , a reason whereby we decided to further study its role in lung cancer. miR-205 expression in H358 and H441 shCtrl and shTMP4 cell clones was validated by qPCR (Supplementary Figure 1B) . 7965403  8117748  8113666  8095585  8112469  7909422  8095364  8095380  8155574  7917885  8176484  7997010  8067140  7997139  7912537  7922846  8177709  8125734  8074714  8110123  7985571  7932733  8110606  8141016  8117900  8158995  8084895  7944164 TMPRSS4   MUC20   LCN1   DDR1   TFPI2   BTNL8   MKX   LOC80154   FAM153B   POM121L1P   DAXX   MOG   FAM129A   DHRS3   CALB2   CYP24A1   CLEC18A   TSPY1   CNN3   ANKRD20A1   TMPRSS11E   TMPRSS11E   MIR205   GUSBP3 Figures 1C and D) . Initially, we assessed whether ectopic expression of miR-205 had a biological effect on proliferation and clonogenicity. MTT proliferation assays indicated that cell clones overexpressing miR-205 had a reduction in cell proliferation rates compared with cells transfected with scramble vector (miR-Scr) in both cell lines tested ( Figure 1C) . Furthermore, the overexpression of miR-205 decreased clonogenic capacity of H2170 and H441 cell lines ( Figure 1D ). These data indicate that miR-205 inhibits cell growth in lung cancer cell lines. As anchorage-independent growth is strongly correlated with tumorigenicity, we then determined whether miR-205 would alter cell growth in soft agar. H2170 cell clones were plated in soft agar and incubated for 2 weeks before counting the number of colonies. As shown in Figure 2A , the ability to form colonies was almost abolished in miR-205-overexpressing clones compared with scramble control. The same results were observed in the H441 cell line (Supplementary Figure 1E) .
A cell cycle analysis by flow cytometry was performed to determine whether the decrease in cell proliferation due to miR-205 upregulation was associated with a cycle arrest. Overexpression of miR-205 produced a significant increase in the percentage of cells in the G 0 /G 1 phase (from 56.44 ± 1.72% to 66.03 ± 1.77%; Po0.05), along with a decrease in the S phase ( Figure 2B ), indicating that miR-205 induced a cell cycle arrest in the H2170 cell line. Similar results were observed in the H441 cell line (Supplementary Figure 1F) . miR-205 inhibits cell migration and adhesion to fibronectin and promotes an epithelial phenotype in lung cancer cells. We next investigated whether miR-205 would modify cell migration in lung cancer cells. For this purpose, H2170 control cells or clones with elevated miR-205 levels were subjected to a migration assay. As shown in Figure 2C , 48 h after plating, upregulation of miR-205 completely blocked the ability of cells to migrate. Migration assays in Boyden chamber could not be performed with the H441 cell line because, in our hands, these cells did not migrate through the transwells. To further confirm the effect of miR-205 on migration through transwells, A549 cells with miR-205 overexpression or control cells (carrying the empty vector) were also used. As shown in Supplementary Figure 1G , similar results to those found for H2170 cells were obtained. In addition, as an alternative to this assay using H441 cells, an in vitro wound healing assay was performed to analyse migration in these cells. Figure 2D and Supplementary Figure 2A show that overexpression of miR-205 caused a reduction in the ability of H441 cells to migrate.
To study the effects of miR-205 on cell-matrix adhesion, we cultured H2170 cells on different substrates. miR-205 overexpression decreased cell adhesion to fibronectin ( Figure 2E ) but not to collagen type I (Supplementary Figure 2B) . A similar tendency was found for H441 cells, although results did not reach statistical significance (data not show).
Different studies have demonstrated that miR-205 regulates EMT by targeting ZEB2 (Gandellini et al, 2009; Matsushima et al, 2011) . As shown in Figure 3A , ZEB1 and ZEB2 mRNA levels were strongly reduced in miR-205-overexpressing cells. The analysis of EMT markers by qPCR and immunofluorescence revealed a marked increase in E-cadherin along with a pronounced decrease in fibronectin in H2170 cells with miR-205 overexpression (Figures 3B-D) . The effect of miR-205 on E-cadherin and fibronectin expression was similar (although less remarkable) in H441 cells compared with H2170 cells (Supplementary Figures 2C  and D) . These results show that miR-205 inhibits EMT and cell motility and promotes an epithelial phenotype. Figure 2E) .
Furthermore, we used a xenograft model to analyse the effect of miR-205 on lung metastasis. In this case, animals were injected with the H2170 clones in the tail vein and monitored by bioluminescence until day 21. At day14th and 21st, a significant increase in light emission in the H2170 miR-Scr group was observed in comparison with the group injected with miR-205-overexpressing cells (Figures 4A and B) . At the end of the study (day 21), animals were killed and lungs were examined for metastatic lesions. Histological analysis confirmed a less tumour burden in mice injected with cells that overexpressed miR-205 ( Figure 4C ). Immunohistochemical analysis of active caspase-3 revealed a higher proportion of apoptotic cells in tumours with increased levels of miR-205 ( Figure 4D ).
Identification of miR-205 targets. We wanted to address the molecular mechanism that causes miR-205 effects in lung cancer. We hypothesised that miR-205 could reduce the expression of target genes that induce EMT and inhibit cell invasion. To identify miR-205 target genes, we compared mRNA expression profiles in H2170 cells overexpressing miR-205 with those of controls (miR-Scr). By microarray analysis, 796 probes displayed a 4two-fold reduction in expression as a result of miR-205 upregulation compared with controls. We searched within our gene list for putative-predicted miR-205 targets using publicly available and commonly used programs, such as TargetScan4, miRBase, PicTar and miRanda. Among the candidates, many were related with cell-cell and cell-matrix adhesion, cell invasion and metastasis (a selected list can be found in Supplementary Table 3) . Importantly, one of the genes was integrin a5 (ITGa5), whose 3 0 -UTR sequence had a perfect complementarity with the seed sequence of miR-205 ( Figure 5A ).
Because ITGa5 is overexpressed in lung cancer (Dingemans et al, 2010) , it promotes invasion of cancer cells (Hood and Cheresh, 2002) and its expression has been linked to TMPRSS4 in colon cancer (Kim et al, 2010) , we focused our attention on this gene. We analysed whether endogenous ITGa5 mRNA and protein levels decreased when miR-205 was overexpressed. We found that miR-205 upregulation in H2170 or H441 lung cancer cells caused a significant reduction in endogenous ITGa5 mRNA levels ( Figure 5B for H2170 cells and Supplementary Figure 2F with an overexpression of miR-205 ( Figure 5D ). To determine whether ITGa5 was a direct target of miR-205, we constructed renilla-based reporters that contained the wild-type or the mutated miR-205 target sequences of the ITGa5 3 0 -UTR. Ectopic expression of miR-205 inhibited the expression of the reporter vector containing the wild-type sequence of ITGa5 3 0 -UTR but not the reporter vector containing the mutation of the seed-miR-205 binding site in the two cell lines tested ( Figure 5E for H2170 cells and Supplementary Figure 2H for H441 cells) . These data show that ITGa5 is a direct target of miR-205 and that miR-205 can reduce ITGa5 mRNA and protein levels.
Knockdown of ITGa5 in lung cancer cells reduces cell migration and cell-matrix adhesion. To examine whether ITGa5 expression could mediate miR-205 regulation of cell proliferation and migration, shRNAs against ITGa5 were transfected in H2170 cells. ITGa5 shRNA efficiently decreased ITGa5 expression, as detected by western blot analysis ( Figure 6A ). ITGa5 depletion resulted in a complete abrogation of cell migration ( Figure 6B ) but no changes in cell proliferation or cell cycle distribution were observed (data not shown).
As integrins are major adhesion molecules involved in cell-ECM interactions, we studied the effects of ITGa5 on cell-matrix adhesion. After culture of these cells on different substrates, we observed that ITGa5 levels modified the adhesiveness to fibronectin ( Figure 6C ) but not to collagen type I (data not shown). All these results provide evidence that inhibition of ITGa5 by miR-205 is responsible, at least in part, for the antitumorigenic effect observed in NSCLC cells with miR-205 upregulation.
Knockdown of ITGa5 inhibits tumour growth in vivo. To further explore whether ITGa5 knockdown would be responsible for the inhibition of tumour growth observed following miR-205 reconstitution, an in vivo experiment was performed. As shown in Figure 6D , subcutaneous xenotransplantation of H2170 cells with ITGa5 depletion caused a significant tumour shrinkage (Po0.05) in comparison with control cells.
Relationship between TMPRSS4 and ITGa5 expression. Having demonstrated that reduction of TMPRSS4 increases miR-205, which targets ITGa5, we studied levels of ITGa5 in shTMP4 cell clones. Figure 6E shows that, in agreement with previous results, ITGa5 levels were lower in shTMP4 clones than in controls, in the three cell lines tested. We also wondered whether there would be a correlation between ITGa5 and TMPRSS4 expression in cell lines. qPCR analysis for ITGa5 was conducted in 30 lung cancer cell lines and its expression was compared with that of TMPRSS4 in our previous publication (Larzabal et al, 2011) . As shown in Figure 6F , 22 out of 30 cell lines expressed ITGa5. Eleven of the TMPRSS4 ( þ ) cells expressed ITGa5 as well, but some TMPRSS4 ( À ) cells were positive for ITGa5 (Supplementary Table 4) . This shows that ITGa5 may be regulated by other proteins in addition to TMPRSS4. On the basis of our findings, we propose a molecular mechanism through which TMPRSS4, regulating miR-205 expression, can modulate ZEB1, ZEB2 and ITGa5 levels to inhibit EMT and metastasis in lung cancer (Figure 7) . 
DISCUSSION
TMPRSS4 has been shown to increase cell motility and invasion, to induce EMT and to promote metastasis in different cancer models, through multiple downstream signalling pathways involving ERK, AKT, Src and Rac1 (Kim et al, 2010) . TMPRSS4 is upregulated in some cancer types, such as colon, pancreas, thyroid and lung (Wallrapp et al, 2000; Kebebew et al, 2005; Kim et al, 2010; Larzabal et al, 2011) . Thus, this serine protease has emerged as a promising diagnostic and therapeutic target in cancer. Nonetheless, the molecular regulation of TMPRSS4 leading to these effects is still unknown. In the present study, we have identified a new molecular mechanism whereby TMPRSS4 regulates integrin a5 levels through the expression of miR-205. Because ITGa5 is strongly involved in the protumorigenic effects elicited by TMPRSS4, the data reported here about this novel molecular axis will help designing therapeutic strategies to inhibit this pathway. Moreover, in the present study we confirm the tumour suppressor role of miR-205 in lung cancer. In order to elucidate the mechanism of action elicited by TMPRSS4 during EMT and metastasis formation, we conducted a microarray analysis where we compared gene expression profiles after TMPRSS4 inhibition in H358 and H441 lung cancer cell lines, with those of mock-transfected cells. As expected, the majority of genes with a differential expression were related with cell invasion and motility, in keeping with the functional role described for this serine protease in some tumour types (Jung et al, 2008; Kim et al, 2010) . One of the upregulated genes was miR-205, a microRNA that has been described as a tumour suppressor (Song and Bu, 2009; Majid et al, 2011) .
MicroRNAs (miRs) are small, non-coding RNAs that negatively regulate gene expression via translational repression or messenger RNA degradation (Bartel, 2004) . MicroRNAs are involved in biologic and pathologic processes, including cell differentiation, proliferation and apoptosis (Kloosterman and Plasterk, 2006) . Accumulating evidence indicates that deregulation of miRs is associated with the development of human cancers and suggests a causal role of miRs in tumour initiation and progression, as they can function as oncogenes or tumour suppressors (Caldas and Brenton, 2005; Chen, 2005) . Recently, studies have shown that miR-205 regulates EMT through the modification of E-cadherin and other adhesion proteins (Bracken et al, 2009; Gibbons et al, 2009) . Expression of the miR-200 family and miR-205 has been shown to be reduced in cells undergoing EMT. These miRs act by directly targeting the 3 0 -UTR sequence of ZEB1 and SIP1 (Gregory et al, 2008; Park et al, 2008) . miR-205 has also been shown to suppress metastatic spread of human breast cancer xenografts in nude mice (Iorio et al, 2009) and to exert a tumour suppressor role by targeting HER3 receptor and VEGF-A in breast cancer (Iorio et al, 2009; and Src in renal cancer (Majid et al, 2011) . In lung cancer, overexpression of miR-205 in cell lines hinders cell migration and invasion (Song and Bu, 2009 ) and its inhibition results in the acquisition of cancer stem cell and EMT properties, which favors tumour progression (Tellez et al, 2011) . Consistent with these reports, we demonstrate that miR-205 was markedly downregulated in lung cancer cell lines compared with non-malignant HBEC lung epithelial cells. Its overexpression strongly reduced cell proliferation and clonogenic survival and caused G 0 /G 1 cell cycle arrest. In addition, we show that forced expression of miR-205 in lung cancer cells impaired migratory and invasive capabilities. Furthermore, we demonstrate that miR-205 expression reduced lung metastasis formation and promoted an epithelial phenotype by inducing E-cadherin and decreasing fibronectin levels. However, the role of miR-205 in lung cancer remains controversial, since some studies indicate a high expression of this miRNA in lung cancer compared with normal lung tissue (Yanaihara et al, 2006; Markou et al, 2008; Lebanony et al, 2009) . Interestingly, expression of miR-205 has been described as a biomarker to distinguish between AC and SCC (Hamamoto et al, 2013; Jiang et al, 2013) . It is worth noticing though, that exposure of HBEC cells to tobacco carcinogens silences miR-205 expression through epigenetic mechanisms, leading to a dedifferentiation programme (Tellez et al, 2011) . Moreover, epigenetic silencing of miRNAs with tumour suppressor features, including miR-205, is emerging as a common hallmark of human tumours (Lujambio et al, 2008) .
Each miRNA has the potential to target hundreds of genes, which harbour sequences in their 3 0 -UTRs that are complementary to the seed region of the miRNA (Lim et al, 2005) . Different targets of miR-205 have been described including, as previously mentioned, ZEB1 and SIP1 (Gregory et al, 2008) , ERBB3 and VEGF-A ), LDL receptor protein 1 (Song and Bu, 2009) and PKCe (Gandellini et al, 2009) . In the present study, we have identified and validated for the first time ITGa5 as a new target of miR-205 in cancer.
Integrins are a family of cell adhesion proteins that activate diverse intracellular signalling molecules and reorganise the actin cytoskeleton to regulate attachment, survival and motility (Giancotti and Ruoslahti, 1999; Hood and Cheresh, 2002) . In NSCLC, expression of particular integrins has been shown to predict the clinical course and prognosis of patients (Adachi et al, 2000; Gogali et al, 2004) . ITGa5 binds to integrin b1 to give rise to the a5b1 heterodimer. Fibronectin stimulates the proliferation of lung cancer cells through a5b1 integrin receptor-mediated signalling; thus knockdown of this integrin reduces tumour burden (Roman et al, 2010) . High expression of ITGa5 is associated with lower overall survival in patients with early stages of NSCLC 0 -UTR reporter activity. All these experiments were repeated at least three independent times. (Dingemans et al, 2010) . Moreover, high ITGa5 levels have been associated with poor prognosis in NSCLC patients with negative lymph nodes (Adachi et al, 2000) . We show here that 22 out of 30 lung cancer cell lines analysed expressed ITGa5. Furthermore, inhibition of this integrin diminishes cancer cell migration, adhesion and tumour growth. These data suggest that ITGa5 may constitute a target worth studying in patients with NSCLC.
A close relationship between acquisition of EMT features and ITGa5 expression has been observed. Inhibition of E-cadherin in ovarian cancer cells causes upregulation of ITGa5 (Sawada et al, 2008) . ZEB2, a transcription factor that represses E-cadherin, upregulates ITGa5 levels through cooperation with Sp1 to induce EMT and invasion in cancer cells (Nam et al, 2012) . In this line, Kim et al (2010) pointed to TMPRSS4 as a new regulator of EMT in colon cancer and suggested that Src, FAK and ERK, which are major downstream effectors of integrins, appeared to be key signalling molecules involved in cell invasion and in the cadherin switch, presumably via regulation of ITGa5 expression. In agreement with these results, we show a downregulation of ITGa5 in H358, H441 and H2170 lung cancer cell lines with an inhibition of TMPRSS4, which confirms the regulation of ITGa5 by TMPRSS4. Therefore, it appears that targeting the novel TMPRSS4/miR-205/ITGa5 axis may be a promising strategy to inhibit EMT and metastasis in NSCLC. In this regard, an antibody targeting integrin a5b1 (volociximab, PDL Biopharma) has been developed and is being currently tested in phase II clinical trials for solid tumours (particularly for renal carcinoma).
In summary, our results provide evidence for the existence of a new molecular connection between two membrane-anchored proteins (ITGa5 and TMPRSS4) that cooperate to foster tumour growth, metastasis and migration, through miR-205. This new P a r e n t a l P a r e n t a l s h C t r l s h C t r l s h T M P 4 P a r e n t a l s h C t r l H187  H209  H345  N417  H510  H446  H23  H441  H2087  H1648  HCCC827  H358  A549  H322  H520  H1703  H2170  H157  H226  HTB58  H1299  H460  97TMI  103H  H661  H727  PC14 intracellular signalling pathway appears to have an important role in the development of lung cancer. TMPRSS4 blockade in tumour cells causes an overexpression of miR-205, resulting in an inhibition of the transcription factors ZEB1 and ZEB2, and ITGa5, which leads to a loss of EMT features. This, in turn, decreases cellmatrix interaction and cell invasiveness, hindering cell migration and metastasis formation. Biological or pharmacological approaches to block TMPRSS4 and ITGa5 may constitute an interesting novel approach to inhibit lung cancer.
